Assetmark Inc. Sells 3,081 Shares of VanEck Biotech ETF (NASDAQ:BBH)

Assetmark Inc. decreased its holdings in VanEck Biotech ETF (NASDAQ:BBH) by 88.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 384 shares of the company’s stock after selling 3,081 shares during the period. Assetmark Inc.’s holdings in VanEck Biotech ETF were worth $60,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of BBH. Truvestments Capital LLC bought a new stake in VanEck Biotech ETF in the 3rd quarter worth approximately $44,000. FSA Wealth Management LLC bought a new stake in VanEck Biotech ETF in the 3rd quarter worth approximately $54,000. Coastline Trust Co bought a new stake in shares of VanEck Biotech ETF in the third quarter worth $59,000. SBI Securities Co. Ltd. bought a new stake in shares of VanEck Biotech ETF in the fourth quarter worth $81,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of VanEck Biotech ETF in the third quarter worth $166,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Up 1.0 %

VanEck Biotech ETF stock opened at $162.66 on Friday. The business has a 50-day simple moving average of $162.68 and a two-hundred day simple moving average of $167.77. The company has a market cap of $396.89 million, a P/E ratio of 30.97 and a beta of 0.85. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64.

VanEck Biotech ETF Announces Dividend

The firm also recently disclosed a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date of this dividend was Monday, December 23rd.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.